Skip to main content

Search

Janssen and UK Government Announce Agreement in Principle for COVID-19 Vaccine

Janssen and UK Government Announce Agreement in Principle for COVID-19 Vaccine

"Ending the current COVID-19 pandemic will take a global effort, and this agreement is an important example of how we can begin to address this significant challenge through collaborative research”

Paul Stoffels, M.D.

Vice Chairman of the Executive Committee and Chief Scientific Officer, Johnson & Johnson

The Janssen Pharmaceutical Companies of Johnson & Johnson, has agreed in principle to collaborate with the UK Government on a global Phase 3 clinical trial to explore its SARS-CoV-2 vaccine candidate. In addition, Janssen has agreed in principle to supply the UK Government with doses of its vaccine candidate, subject to its successful clinical development and regulatory approval.

“We are delighted to work with the UK Government on the global Phase 3 clinical programme for our COVID-19 vaccine candidate, and to ensure it is made available to citizens around the world, if proven to be effective with a good safety profile. Ending the current COVID-19 pandemic will take a global effort, and this agreement is an important example of how we can begin to address this significant challenge through collaborative research,” said Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scientific Officer, Johnson & Johnson.

The trial will explore the two-dose regimen of Janssen’s SARS-CoV-2 vaccine candidate, Ad26.COV2.S, and will run in parallel to a Phase 3 trial investigating the single-dose regimen. Planning is underway for the Phase 3 clinical development programme, which is subject to results of the ongoing Phase 1/2a trials and approval of regulators.

In addition, a final agreement will be determined in due course under which the UK Government would initially purchase 30 million doses of Janssen’s vaccine candidate on a not-for-profit basis for emergency pandemic use, with the option for an additional purchase by the UK Government of up to a further 22 million vaccine doses.

Click here to find out more about our response to COVID-19.

 

 

 

 

Job code: EM-39747                               Date of preparation: August 2020